ELLIOT SUTTON-INOCENCIO: Open Payments
NPI 1346929312 · NATIONAL CITY, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$878 in 24 payments from 7 companies in 2025. Trend: 2023 $13 · 2024 $111 · 2025 $878
Food & beverage: $878
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 4 | $216 |
| Teva Pharmaceuticals USA, Inc. | 2 | $207 |
| E.R. Squibb & Sons, L.L.C. | 9 | $189 |
| Alkermes, Inc. | 3 | $156 |
| Otsuka America Pharmaceutical, Inc. | 4 | $77 |
| ABBVIE INC. | 1 | $19 |
| Janssen Pharmaceuticals, Inc | 1 | $15 |
Products named: INGREZZA, COBENFY, LYBALVI, UZEDY, AUSTEDO XR, REXULTI, ARISTADA, VRAYLAR.
Industry payments across CA — which companies pay providers there.
